

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## UMP HEALTHCARE HOLDINGS LIMITED

### 聯合醫務集團有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 722)**

**(1) RETIREMENT OF CHIEF EXECUTIVE OFFICER;  
(2) APPOINTMENT OF CO-CHIEF EXECUTIVE OFFICER;  
AND  
(3) APPOINTMENT OF VICE CHAIRMAN**

The Board of the Company announces that the following changes will take effect from 1 January 2023:

1. Dr. SUN Yiu Kwong will retire as CEO but remain as Chairman of the Company;
2. Dr. SUN Man Kin, Michael and Ms. KWOK Cheuk Kwan, Jacquen will be appointed as Co-CEO of the Company; and
3. Dr. SUN Man Kin, Michael will be appointed as Vice Chairman of the Company.

#### **RETIREMENT OF CHIEF EXECUTIVE OFFICER**

The Board of Directors (the “**Board**”) of UMP Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that, given his age, Dr. SUN Yiu Kwong (“**Dr. YK SUN**”) has informed the Board of his wish to retire from his role as the chief executive officer (“**CEO**”) of the Company with effect from 1 January 2023. With the full support and agreement of the Board, Dr. YK SUN will remain as the chairman (the “**Chairman**”) and an executive director of the Company (a “**Director**”) after his retirement as the CEO. Upon Dr. YK SUN’s retirement, the Company will comply with the code provision C.2.1 of separating the roles of the Chairman and the CEO under the Corporate Governance Code as set out in Appendix 14 to the Rules Governing the Listing of Securities (the “**Listing Rules**”) on the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Dr. YK SUN has confirmed that he has no disagreement with the Board, and that he is not aware of any matters relating to his retirement that need to be brought to the attention of the Stock Exchange and the shareholders of the Company. Dr. YK SUN has also confirmed that he has no claim against the Company whatsoever whether in respect of fees, remunerations or compensations in respect of the retirement.

The Board would like to express its sincere gratitude to Dr. YK SUN for his invaluable contributions to the Company during his tenure of service as the CEO.

## **APPOINTMENT OF CO-CHIEF EXECUTIVE OFFICER**

The Board is pleased to further announce that with effect from 1 January 2023, Dr. SUN Man Kin, Michael (“**Dr. Michael SUN**”) and Ms. KWOK Cheuk Kwan, Jacquen (“**Ms. KWOK**”) will be appointed as co-chief executive officer (“**Co-CEO**”) of the Company. Upon the appointment, each of Dr. Michael SUN and Ms. KWOK will continue to be executive Directors. In light of Ms. KWOK’s new role as Co-CEO of the Company, Ms. KWOK will cease to be the managing director of the Company accordingly.

### ***Biographical details of Dr. Michael SUN are set out as follows:***

Dr. Michael SUN, aged 44, was appointed as a Director on 18 August 2015 and re-designated as an executive Director on 29 August 2015. He is a specialist in Radiology and along with Ms. KWOK, he is responsible for building, consolidating, and strengthening professional network of the Group and the overall guidance of planning and development of the Group in the future. Dr. Michael SUN has over 15 years of experience in medicine and has been the chief radiologist of the Group since July 2012. He is currently a radiologist, a director and a shareholder of ProCare Medical Imaging and Laboratory Centre Limited, a non-wholly owned subsidiary of the Company. He is also a consultant radiologist of the Group and a director of various members of the Group.

Dr. Michael SUN obtained a Bachelor of Medicine, Bachelor of Surgery from the University of Hong Kong in December 2002. He became a Fellow of the Royal College of Radiologist in October 2007 and a Fellow of the Hong Kong College of Radiologists in October 2010. He also became a Fellow of the Hong Kong Academy of Medicine in the specialty of Radiology in June 2010.

Dr. Michael SUN is the son of Dr. YK SUN and the brother-in-law of Mr. Tsang On Yip, Patrick (an executive Director). He is also a director of East Majestic Group Limited which is a controlling shareholder of the Company and wholly-owned by Dr. YK SUN.

Dr. Michael SUN is beneficially interested in 18,233,958 shares of the Company (the “**Shares**”), representing approximately 2.3% of the issued share capital of the Company. He is also interested in (i) 1,500,000 underlying Shares granted to him by the Company under the Post-IPO Share Option Scheme on 6 November 2018; and (ii) 1,000,000 underlying Shares granted to him by the Company under the Post-IPO Share Option Scheme on 26 May 2021. Dr. Michael SUN was also beneficially interested in 625 shares (representing approximately 6.25%) and 95 shares (representing approximately 6.33%) in ProCare Medical Imaging & Laboratory Centre Limited and Causeway Bay MRI Centre Limited respectively, both being associated corporations of the Company within the meaning of the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong.

Dr. Michael SUN has entered into a service contract with the Company for his directorship for a term of three years commencing from 27 November 2021, subject to retirement by rotation and re-election at annual general meetings of the Company pursuant to the articles of association of the Company. The total emoluments (including Director’s fee, salary, bonus and other benefits as well as the value of share options granted) paid to Dr. Michael SUN for the year ended 30 June 2022 amounted to approximately HK\$449,000. Dr. Michael SUN has not entered into a separate service contract for his duties as a Co-CEO of the Company and the terms and conditions of his existing service contract shall remain unchanged. Dr. Michael SUN’s remuneration will be subject to review and adjustment as determined by the Board after considering the recommendation of the remuneration committee of the Board (the “**Remuneration Committee**”).

Save as disclosed above, as at the date of this announcement, Dr. Michael Sun does not (i) have any relationship with any Directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong); and (iii) hold any other position with the Company and any of its subsidiaries. Dr. Michael Sun does not hold any directorship in any listed companies in Hong Kong or overseas in the last three years.

Save as disclosed above, there are no other matters concerning the appointment of Dr. Michael SUN that need to be brought to the attention of the shareholders of the Company nor any information to be disclosed pursuant to the requirements of Rule 13.51(2) (h) to (v) of the Listing Rules.

***Biographical details of Ms. KWOK are set out as follows:***

Ms. KWOK, aged 54, was appointed as a Director on 5 November 2014 and re-designated as an executive Director on 29 August 2015. Along with Dr. Michael SUN, she is responsible for the overall guidance of planning and development of the Group in the future and initiating and leading business projects in collaboration with medical insurance companies and corporate customers. Ms. KWOK is also responsible for internal operations to enhance operational efficiency and develop the Group's corporate expansion in Hong Kong and Mainland China. Ms. KWOK is one of the key members in establishing the administration arm of the Group. She has over 25 years of experience in health schemes management and providers network administration to support the healthcare plan's implementation in the Group's network. She is actively involved in developing the infrastructure of the Group such as information technology platforms and medical network facilities. In the recent years, Ms. KWOK is also leading and managing corporate development, merger and acquisition investments, and business expansion for the Group.

Ms. KWOK is also a director of various companies of the Group. Ms. KWOK obtained a Bachelor of Arts in International Business Studies (Hons) from the City University of Hong Kong in November 1991 and obtained a Bachelor of Laws from Peking University in July 1996. She also obtained a Master of Science in Management (Health Services Management) from the Hong Kong Polytechnic University in November 2003.

Ms. KWOK is beneficially interested in 17,948,657 Shares, representing approximately 2.26% of the issued share capital of the Company. She is also interested in (i) 1,500,000 underlying Shares granted to her by the Company under the Post-IPO Share Option Scheme on 6 November 2018; and (ii) 1,000,000 underlying Shares granted to her by the Company under the Post-IPO Share Option Scheme on 26 May 2021.

Ms. KWOK has entered into a service contract with the Company for her directorship for a term of three years commencing from 27 November 2021, subject to retirement by rotation and re-election at annual general meetings of the Company pursuant to the articles of association of the Company. The total emoluments (including Director's fee, salary, bonus and other benefits as well as the value of share options granted) paid to Ms. KWOK for the year ended 30 June 2022 amounted to approximately HK\$4,487,000. Ms. KWOK has not entered into a separate service contract for her duties as a Co-CEO of the Company and the terms and conditions of her existing service contract shall remain unchanged. Ms. KWOK's remuneration will be subject to review and adjustment as determined by the Board after considering the recommendation of the Remuneration Committee.

Save as disclosed above, as at the date of this announcement, Ms. KWOK does not (i) have any relationship with any Directors, senior management, substantial shareholders (as defined in the Listing Rules) or controlling shareholders (as defined in the Listing Rules) of the Company; (ii) have any interest in the securities of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap.571 of the Laws of Hong Kong); and (iii) hold any other position with the Company and any of its subsidiaries. Ms. KWOK does not hold any directorship in any listed companies in Hong Kong or overseas in the last three years.

Save as disclosed above, there are no other matters concerning the appointment of Ms. KWOK that need to be brought to the attention of the shareholders of the Company nor any information to be disclosed pursuant to the requirements of Rule 13.51(2) (h) to (v) of the Listing Rules.

### **APPOINTMENT OF VICE CHAIRMAN**

The Board is pleased to further announce that with effect from 1 January 2023, Dr. Michael SUN will be appointed as Vice Chairman of the Company to assist Dr. YK SUN in ensuring the effectiveness of the Board and operation of its committees (including the leadership and governance of the Company, et cetera).

The Board congratulates Dr. Michael SUN and Ms. KWOK on their new appointments and looks forward to their continuous contribution to the Group's business and development.

By Order of the Board  
**UMP Healthcare Holdings Limited**  
**SUN Yiu Kwong**  
*Chairman and Chief Executive Officer*

Hong Kong, 7 December 2022

*As at the date of this announcement, the Executive Directors of the Company are Dr. SUN Yiu Kwong (Chairman and Chief Executive Officer), Ms. KWOK Cheuk Kwan, Jacquen (Managing Director), Mr. TSANG On Yip, Patrick, Dr. SUN Man Kin, Michael, Mr. LEE Kar Chung, Felix and Dr. LEE Pak Cheung, Patrick; and the Independent Non-executive Directors are Mr. LEE Luen Wai, John, Dr. LI Kwok Tung, Donald, Mr. YEUNG Wing Sun, Mike and Mr. CHAU, Chit Jeremy.*